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ABSTRACT
Current approaches to assessing preclinical anticancer activity do not reliably 
predict drug efficacy in cancer patients. Most of the compounds that show remarkable 
anticancer effects in preclinical models actually fail when tested in clinical trials. We 
blame these failures on the complexity of the disease and on the limitations of the 
preclinical tools we require for our research. This manuscript argues that this lack of 
clinical response may also be caused by poor in vitro and in vivo preclinical designs, in 
which cancer patients’ needs are not fully considered. Then, it proposes two patient-
oriented tests to assess in vitro and in vivo anticancer activity and to help validate 
drug candidates for clinical evaluation.
INTRODUCTION
Many cancer patients are diagnosed with or 
develop distant metastasis. Despite the recent approval 
of numerous anticancer drugs [1], most of these patients 
do not overcome the disease. For example, over 50% of 
people diagnosed with lung cancer have distant metastasis 
at the time of diagnosis, and only 4% of them survive 
more than five years. The prognosis for patients with 
other common metastatic cancers is not much better. The 
five-year relative survival rate for patients with metastasis 
to distant sites is 28% in prostate cancer, 24% in breast 
cancer, 13% in colorectal cancer, 3% in liver cancer and 
2% in pancreatic cancer [2]. Many patients diagnosed with 
these common cancers eventually die from the disease 
despite surviving five years after diagnosis. Because 
advanced cancers need to be treated with drugs, there is an 
urgent need to develop better pharmacological therapies.
The first step to developing better treatments is the 
selection of good compounds or strategies for testing. 
For this purpose, understanding the disease is important 
to find better ways to exploit its weaknesses. Given the 
limited progress made to date in the treatment of advanced 
cancers, questioning the established views and considering 
unconventional approaches may also be important. The 
aim of this research perspective is not to review or propose 
potential anticancer strategies.
Testing the drug candidates using robust preclinical 
models is the next crucial step to developing better 
treatments. These models should not only identify the 
best drug candidates, but should also predict whether their 
anticancer potential is high enough to deserve clinical 
evaluation. An inadequate preclinical design may result 
in the selection of poor candidates, which may lead to a 
substantial allocation of preclinical and clinical resources 
to ineffective compounds. An inadequate design may also 
result in a failure to identify new drugs that could change 
the lives of cancer patients. 
Current preclinical models do not reliably identify 
the best drug candidate in a group of compounds [3]. For 
instance, the selected candidate from a library of over 
three hundred thousand compounds [4] was found to 
be more toxic to normal cells than to cancer cells [5,6]. 
These models do not reliably predict drug efficacy in 
patients either; most of the candidates that show efficacy 
in preclinical models actually fail when tested in clinical 
trials [7-9]. 
Researchers blame these failures on the complexity 
of the disease and on the limitations of the preclinical 
tools we require for our research [9]. Here I argue that 
this lack of clinical response may also be caused by poor 
in vitro and in vivo preclinical designs, in which cancer 
patients’ needs are not fully considered. Then, I propose 
two patient-oriented tests to assess preclinical anticancer 
activity and predict drug efficacy in cancer patients more 
reliably.
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Anticancer potency in malignant cells and 
antitumor activity in animal models are poor 
predictors of clinical response
Many drug candidates are proposed for clinical 
evaluation based on their ability to target cancer cells at 
low concentrations and to induce antitumor activity in 
animal models. Despite its widespread use, this approach 
does not fully consider cancer patients’ needs and may 
therefore result in a poor selection of drug candidates for 
clinical development. 
Cancer patients need drugs that improve the 
efficacy of the current pharmacological treatments. 
Accordingly, drugs are not approved for cancer therapy 
unless they match or improve the efficacy (survival rate) 
of the standard treatments when tested in Phase III clinical 
studies. Testing whether or not the experimental treatment 
improves the survival rate of the standard treatment would 
be a reasonable way of assessing anticancer activity in 
animal models. Instead of assessing improvements in 
survival, researchers frequently evaluate the magnitude of 
the antitumor response induced by the drug candidate in 
rodent models. Since researchers often measure different 
parameters in animal and human studies, and since the 
magnitude of the drug response in rodents and humans 
may be rather different, it is not surprising that the 
responses observed in preclinical in vivo models are not 
reproduced in clinical trials.
Researchers assessing anticancer activity in 
vitro often misunderstand cancer patients’ needs; this 
may result in a poor selection of drug candidates in 
the screening step of the drug discovery process [3]. 
Cancer patients do not need drugs that kill cancer cells 
at low concentrations. They do not need drugs that act 
on particular targets involved in cancer cell proliferation 
and survival either. They need drugs that kill their cancer 
cells at concentrations that do not significantly affect 
their healthy cells. If a drug targets cancer cells at low 
concentrations but also targets normal cells at similar 
concentrations, the highest drug doses tolerated by 
the patients will be insufficient to reach the tissue drug 
concentrations required to eliminate their cancer cells. If 
a drug kills cancer cells without significantly affecting 
healthy cells, it does not matter much its pharmacological 
targets or the concentration at which it kills the cancer 
cells. A reasonable way of assessing anticancer activity in 
vitro would be to test if the drug candidate improves the 
ability of the standard drugs to kill cancer cells without 
significantly affecting nonmalignant cells [3].
Instead of looking for compounds that improve 
the selectivity (in vitro) and the survival rate (in vivo) 
of the existing pharmacological treatments, researchers 
typically look for compounds that target malignant cells 
at low concentrations and induce antitumor activity in 
animal models. For example, Wang et al. [4] screened a 
library of 359,484 compounds and found that the cardiac 
glycoside bufalin was a potent inhibitor of the steroid 
receptor coactivators SRC-3 and SRC-1. Because bufalin 
could also inhibit the proliferation of human breast cancer 
cells at very low concentrations and induce antitumor 
activity in mice transplanted with human breast cancer 
cells, the authors discussed that this compound could 
have potential for cancer therapy [4]. Likewise, Denicolai 
et al. [10] screened a chemical library of 1,120 compounds 
and selected the cardiac glycoside proscillaridin A based 
on its ability to target glioblastoma cell lines potently 
(nanomolar concentrations). Proscillaridin A also induced 
anticancer activity in mice xenotransplanted with human 
cancer cells, and the authors suggested that this compound 
was a promising chemotherapeutic agent [10]. 
It is important to recognize that the ability of a 
compound to target cancer cells at low concentrations 
does not reliably predict its ability to kill cancer cells 
selectively. For example, the cardiac glycoside bufalin 
targets breast cancer cells at very low concentrations 
[4], but it is more cytotoxic to breast healthy cells than 
to breast cancer cells [5,6]. We have also observed that 
the most cytotoxic compound in a series of aziridine 
derivatives was 7 times more toxic to normal cells than 
to cancer cells, while a less potent compound of the series 
was over 50 times more cytotoxic to breast cancer cells 
than to several types of normal cells [11].
It is also important to note that the ability of a 
compound to induce antitumor activity in animal models 
does not reliably predict its ability to selectively kill human 
cancer cells versus human healthy cells. Rodent models 
can show the selectivity of a compound in human cancer 
cells versus rodent normal cells (xenograft models), or in 
rodent cancer cells versus rodent normal cells (allograft 
and spontaneous models). However, animal models 
cannot show if a compound can selectively kill human 
cancer cells versus human normal cells. This distinction 
is important to avoid experimental artifacts caused by 
species differences in drug sensitivity. For example, we 
have observed that rodent cells are extremely resistant 
(over 1000-fold) to the cytotoxicity of cardiac glycosides 
when compared to human cancer and nonmalignant cells 
[12]. It is therefore relatively easy to find a marked in 
vivo anticancer activity if one transplants human cancer 
cells into mice and then treats the animals with a cardiac 
glycoside such as bufalin or proscillaridin A [4,10,13-16]. 
This activity, however, is probably caused by the ability 
of these compounds to selectively kill human cells versus 
rodent cells rather than by their ability to selectively kill 
cancer cells [6,12,17-19]. The marked antitumor activity 
of these compounds in xenograft models is unlikely to be 
reproduced in clinical trials.
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Two patient-oriented tests to assess preclinical 
anticancer activity
These tests are designed to detect whether or not 
an experimental treatment is better than the standard 
treatment used in cancer patients. They can help 
researchers decide whether to propose a drug candidate for 
clinical evaluation. They can also be used as standalone 
tests to assess preclinical anticancer activity. They are 
based on setting suitable experimental conditions to 
answer two questions: Can the drug candidate improve 
the ability of the existing drugs to selectively kill cancer 
cells versus a variety of nonmalignant cells? Can the drug 
candidate improve the survival of the standard treatment 
when tested under equivalent experimental conditions in 
animal models representative of patients for whom the 
new drug is intended? A basic protocol that includes both 
tests is proposed in Figure 1.
The in vitro test has been described previously 
[3,20]. It consists of (1) exposing cancer cells and a 
variety of nonmalignant cells to the drug candidate 
and to the standard drugs used to treat patients with 
Figure 1: Basic protocol to assess preclinical anticancer activity. It can be used as a standalone tool to evaluate the activity 
of novel compounds. The tests can also be used to help validate drug candidates that have shown efficacy in other preclinical tests. The 
experimental treatments and the standard treatments can be single drugs or drug combinations. The crossed-out arrows can be bypassed in 
specific situations (e.g., when the drug does not kill cancer cells through a direct cytotoxic mechanism or when the pharmacokinetics or 
pharmacodynamics of the drug in rodents and humans are not similar). See text for details.
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the selected cancer, (2) estimating cell viability with a 
simple cytotoxicity test (e.g., SRB assay, MTT assay), 
(3) calculating one or several cytotoxicity parameters 
(e.g., IC50, IC90, LC50) for each drug in each cell type, (4) 
calculating a selectivity index for each drug (e.g., dividing 
the IC50 value in the nonmalignant cells by that in the 
cancer cells) and (5) comparing the selectivity indices 
of the experimental drugs with those of the standard 
anticancer drugs [3,20]. 
Several aspects should be considered for 
implementing the in vitro test. The cancer cells and 
nonmalignant cells should be human to avoid unreal 
selectivity values caused by species differences in drug 
sensitivity. For example, if we test a cardiac glycoside in 
human cancer cells versus rodent normal cells, we will 
find a high selectivity caused by the resistance of rodent 
cells to the cytotoxic effects of these compounds [12]. 
Selecting nonmalignant cells from a variety of tissues is 
also essential for implementing this approach robustly. We 
should always keep in mind that a high toxicity to normal 
cells from just one particular tissue may cause that the 
maximum doses tolerated by the patients are insufficient 
to reach the drug concentrations required to eliminate 
their cancer cells. A selection of nonmalignant cells from 
tissues commonly affected by cancer pharmacotherapy 
would help us predict dose-limiting toxicity to normal 
tissues. Selecting nonmalignant cells from the same tissue 
than that of the cancer cells is also important to avoid 
unreal selectivity values originated by tissue differences 
in drug sensitivity. For example, if we are looking for 
drugs for brain cancer, we should select brain cancer cells 
and a variety of nonmalignant cells from several tissues 
including the brain. This would prevent us from choosing 
drug candidates that induce selective cytotoxicity 
towards a particular tissue (e.g., brain) but have a limited 
selectivity towards cancer cells (e.g., ellipticinium 
derivatives ) [21,22]. 
The in vitro test can be used to assess the anticancer 
potential of drug combinations. Currently, the therapeutic 
potential of a drug combination is typically evaluated 
by testing in cancer cells if its cytotoxicity is enhanced 
(potentiation factor) or synergistically increased 
(combination index) in relation to the cytotoxicity induced 
by each drug individually. This approach assumes that 
increasing the cytotoxic potency of a drug combination 
in cancer cells will also increase its therapeutic potential. 
The key feature of an efficient anticancer drug or drug 
combination is their ability to kill cancer cells selectively, 
and not their ability to kill cancer cells potently. A drug 
combination that induces a strong cytotoxic synergism 
in cancer cells will not be clinically effective if it 
induces a stronger synergism in nonmalignant cells. 
A drug combination that induces an antagonism in 
cancer cells may be clinically effective if it induces a 
stronger antagonism in nonmalignant cells. As discussed 
elsewhere, it does not matter whether a drug combination 
is synergistic, additive or even less than additive for 
cancer cells. What is important is that such a combination 
has a high selectivity towards cancer cells versus normal 
cells [23,24]. But there is something else to consider. 
The drug combination should not just be more selective 
than the individual drugs. It should be more selective 
than the standard drug or drug combination used to treat 
patients with the selected cancer. A drug combination 
that induces synergism in cancer cells and antagonism 
in nonmalignant cells will not be clinically useful if its 
selectivity towards cancer cells is much lower than that of 
the standard treatment. The in vitro test can reveal whether 
an experimental drug combination improves the selectivity 
of the standard drug or drug combination used in cancer 
therapy.
The preclinical in vivo test shown in Figure 1 seeks 
to establish the most suitable experimental conditions 
for detecting whether the drug candidate is better than 
the existing treatment. It seeks to mimic the test that 
every anticancer drug needs to pass to be approved for 
human use: phase III clinical trials. In these trials, the 
experimental treatments are compared with the current 
standard treatments. To pass this test and receive approval 
for use in cancer patients, the new drugs should be at least 
as effective as the existing anticancer drugs. 
Improved survival is the standard endpoint to 
assess effectiveness in phase III trials. Because most 
cancers requiring pharmacotherapy are difficult to cure, 
prolonging patient survival is a major goal of cancer 
pharmacotherapy. In addition, the moment someone dies 
can be measured easily and unequivocally. Assessing 
survival does not depend on measuring the size of tumors 
that are sometimes difficult to measure or even locate 
(e.g., micrometastasis). Furthermore, survival accounts 
for any increase in the death rate due to long-term drug 
toxicity. Measurement of tumor shrinkage in response to 
treatment provides useful information; however, it is not a 
proof that a treatment is truly beneficial. Tumor shrinkage 
in response to treatment is the typical endpoint for phase 
II trials, but not for phase III trials. Because phase III 
trials are regarded as the most rigorous studies for testing 
whether new treatments work, improved survival should 
also be the standard endpoint to assess effectiveness in 
animal models.
In phase III clinical trials, the experimental 
treatment and the standard treatment are tested under 
the most favorable conditions. Although finding these 
conditions may be difficult, it is widely accepted that 
the drugs should be tested at the maximum tolerated 
dose (MTD) determined in phase I (or phase II) clinical 
studies. A phase III trial would never receive approval 
if the experimental drug were planned to be tested at the 
MTD and the standard treatment at one-half of the MTD. 
The match would not be fair. Selecting equitoxic drug 
doses should be equally important to assess drug efficacy 
in animal models. This is not always the case, however. 
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The determination of MTD in rodents is somewhat 
different from in humans. Because mice cannot tell us if 
they are experiencing unacceptable side effects, higher 
doses are required to determine this parameter. A fraction 
of the MTD value (e.g., 0.375 x MTD and 0.25 x MTD: 
http://dtp.nci.nih.gov/branches/btb/acute_tox.html) could 
be used for implementing the in vivo test. 
Patients with localized and resectable tumors are not 
eligible for phase III clinical trials evaluating the efficacy 
of new pharmacological treatments. The reason is that the 
participants of these trials should represent the population 
that would eventually receive the new drug, and these 
patients do not represent such a population. These patients 
are usually treated successfully with surgery and are not 
expected to benefit from the new treatment. Something 
that is unacceptable in human studies is however 
acceptable in animal studies. We commonly use mice with 
localized and resectable tumors to evaluate the efficacy 
of our experimental drugs. Although we could easily cure 
these mice by surgical resection of the tumors, we spend 
resources trying to find drugs that will never improve the 
efficacy of a treatment that we already have. Selecting 
animal models representing the patients who are expected 
to receive the new treatment seems to be a more reasonable 
approach to assessing anticancer activity in vivo. Because 
most patients requiring pharmacotherapy have metastatic 
disease, selecting animal models of metastasis should be a 
priority in most situations.
Strengths and limitations of the tests
The most important strength of the tests is that 
they are designed to detect the type of drugs that cancer 
patients need. Cancer patients need drugs that improve 
the efficacy of the existing pharmacological treatments, 
and both tests measure whether or not the drug candidate 
improves the efficacy of these treatments. Establishing the 
best parameter to measure efficacy in vitro and in vivo is 
important. The tests propose that selectivity and survival 
are the best parameters to determine drug efficacy in vitro 
and in vivo, and establish experimental conditions to 
measure these parameters robustly. 
Another important advantage of these tests is that 
they make our preclinical tools better. Depending on the 
cell lines or animal models we use for testing our drugs, 
the magnitude of the drug response may be rather different. 
This makes extrapolation and comparison of results 
problematic. It also makes it difficult to know how much 
effect we should observe to say that our drug is promising. 
Therefore, when the extent of the response in two models 
is not similar, we usually consider that these models may 
be inadequate for testing our drugs. For example, the 
NCI60 human tumor cell line anticancer drug screen did 
not include nonmalignant cell lines as controls because 
the normal cell types available at that time were either 
very resistant or very sensitive to the cytotoxic activity of 
the tested anticancer drugs [22]. The researchers involved 
in the development of the screen probably thought that 
the resistant normal cells would underestimate, and the 
sensitive normal cells would overestimate, the anticancer 
potential of the experimental compounds. The tests 
discussed in this manuscript make our preclinical tools 
better because they focus on whether the experimental 
drug improves the activity of the standard drug, and not 
on the magnitude of their effects in particular cell types or 
animal models. In these tests, it does not matter whether 
the selectivity of the drug candidate in particular cell 
types is 2, 10 or 100. What matters is if its selectivity is 
higher than that of the drugs used in cancer therapy. Those 
normal cell types that were considered to be inadequate 
for the NCI anticancer drug screen would be adequate for 
the in vitro test. With the in vitro and the in vivo tests, it is 
easy to know how much activity we should observe to say 
that our drug is promising: we should improve the activity 
of the standard anticancer drugs.
The implementation of these tests may lead to an 
important saving of research resources. For example, large 
amounts of resources have been dedicated to investigate 
the anticancer potential of the curry constituent curcumin. 
We have learned from thousands of research studies that 
curcumin modulates numerous molecular targets involved 
in cancer cell death and proliferation pathways. Curcumin 
can also kill many types of cancer cells in vitro and induce 
antitumor activity in xenograft models [25-27]. Several 
clinical trials have evaluated the anticancer activity of 
curcumin, and others are ongoing or recruiting participants 
(https://clinicaltrials.gov/). None of the completed clinical 
trials, however, has shown relevant anticancer effects 
so far. Unfortunately, none of the over 2,500 papers in 
PubMed that contain the terms “curcumin” and “cancer” 
has assessed under adequate experimental conditions 
whether curcumin improves the selectivity or survival 
of the standard anticancer drugs. A single research work 
assessing the selectivity of curcumin and of a variety 
of anticancer drugs in an adequate panel of cancer and 
nonmalignant cell lines could reveal that this huge 
amount of preclinical and clinical resources may not have 
been spent in the best interests of cancer patients. Since 
curcumin typically kills cancer cells in the 5-50 μM range 
[28], we evaluated its cytotoxic activity in lung cancer 
cells and lung nonmalignant cells at this concentration 
range and observed an identical cytototoxic profile in both 
cell lines [29]. The implementation of the protocol shown 
in Figure 1 would not only lead to an important saving 
of resources, but would also prevent many animals and 
patients from receiving ineffective drugs.
Advanced technologies are not required for 
implementing these tests. This is an important advantage 
for researchers with limited budgets. Any research team 
with cell culture and animal facilities can put these tests 
into practice and assess preclinical anticancer activity 
robustly. 
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These tests have limitations, however. The in vitro 
test has the typical limitations of all in vitro investigations. 
Because in vitro conditions do not represent in vivo 
conditions faithfully, drugs that work in vitro may 
not work in vivo, and vice versa. In addition, this test 
would not be suitable to assess the anticancer activity 
of drug candidates that do not kill cancer cells through 
a direct cytotoxic mechanism, such as immunostimulant 
compounds. Modified or alternative experimental 
conditions should be established for assessing the in vitro 
anticancer activity of these compounds.
Human cancers cannot be faithfully reproduced in 
mice. The following most important limitation of the in 
vivo test comes from the fact that the pharmacokinetics 
and pharmacodynamics of a drug in rodents may be 
different from in humans. In two species, the same drug 
may not only induce different effects or similar effects 
with different intensities, but may also be processed 
differently. These variations between species are 
commonly caused by differences in target cell sensitivity 
and in drug metabolism, and make extrapolations between 
rodents and humans difficult. As discussed previously, 
cardiac glycosides induce marked antitumor effects in 
mice transplanted with human cancer cells; this probably 
happens because human cells are much more sensitive 
than rodent cells to the cytotoxicity of these compounds. 
Experimental artifacts caused by species-differences in 
drug sensitivity could be prevented or detected by testing 
the cytotoxicity of the experimental drugs and the standard 
drugs in human cancer cells, human nonmalignant cells 
and rodent cells [12]. If the drug candidate improves 
the survival of the standard drug in rodent models, 
these cytotoxicity experiments would reveal if the 
survival improvement is caused by species-differences 
in sensitivity rather than by a selective anticancer effect. 
Species differences in drug metabolism may also lead to 
experimental artifacts. A standard anticancer drug may 
be metabolized in rodents much more extensively than in 
humans. Its activity in rodents would therefore be reduced, 
and it would be easier for an experimental drug to show 
a survival benefit. This benefit, however, would not occur 
in humans. The in vivo test could also underestimate the 
efficacy of drug candidates that are metabolized in rodents 
much more extensively than in humans. Measuring the 
levels of the experimental drugs and standard drugs 
in plasma and target tissues may assist researchers in 
detecting possible experimental artifacts caused by 
species-differences in drug distribution and metabolism. 
CONCLUDING REMARKS
Survival in patients with the most common 
metastatic cancers is low [2]. Because the main form of 
treatment for these patients is pharmacotherapy, many 
research resources are invested to develop new anticancer 
drugs. As a result, thousands of research papers assessing 
preclinical anticancer activity are published every year, but 
very few clinical successes are produced. Clinical trials in 
oncology actually have the highest failure rate compared 
with other therapeutic areas [7,9]. It is broadly accepted 
that the limitations of preclinical tools, such as inadequate 
cancer cell lines and mouse models, make it difficult for 
even the best scientists working in optimal conditions to 
make a discovery that will ultimately have an impact in 
the clinic [9]. 
This research perspective argues that the high failure 
rate of clinical trials in oncology may also be caused by 
an inadequate use of our preclinical tools. If researchers 
involved in cancer drug discovery (e.g., authors, reviewers 
and editors) do not use or request reliable preclinical tests 
for assessing anticancer activity, the problem of low 
clinical trial success rates will not be solved by providing 
the cancer research community with collections of well-
characterized cancer cell lines, with novel animal models 
or with the most sophisticated technologies. Despite using 
these tools, researchers may still consider that a drug 
deserves clinical evaluation when it targets cancer cells 
at low concentrations and induces a marked inhibition 
of tumor growth in mice. If the cytotoxic mechanism of 
the drug is mediated by a novel therapeutic target and is 
unraveled with advanced technologies, this research work 
may well be published in a prestigious scientific journal, 
which may lead to a clinical trial with a high probability 
of failure.
Two simple and cost-effective tests for assessing 
preclinical anticancer activity are proposed in this 
manuscript. Because cancer patients need drugs that 
improve the efficacy of the existing treatments, the aim of 
both tests is to detect this type of drugs. After discussing 
that selectivity and survival are the best parameters to 
measure anticancer efficacy in vitro and in vivo, the tests 
establish experimental conditions for detecting these 
parameters robustly. Despite having limitations, these 
tests can help researchers assess the in vitro and in vivo 
anticancer activity of their compounds. They can also 
be useful for deciding whether or not a drug candidate 
deserves clinical evaluation. Clinical trial failure rates 
would probably decrease if the drug candidates had 
to pass both tests before reaching clinical trials. Drug 
candidates passing both tests should also show that their 
anticancer activity is not an experimental artifact caused 
by pharmacokinetic and pharmacodynamic differences 
between rodents and humans. A possible way of 
minimizing these artifacts has been proposed. 
The following strategies would facilitate the 
implementation of these tests in the cancer research 
community. Cancer research organizations could take 
the lead in assembling and providing researchers with 
an adequate collection of cell lines (malignant and 
nonmalignant) and animal models for each type of cancer. 
They could also provide researchers with detailed in 
vitro and in vivo protocols to assess anticancer activity 
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in these cancers. Results (e.g., selectivity indices and 
survival rates) obtained with the standard drugs under 
the experimental conditions of these protocols would 
help researchers know what we should match or improve. 
Researchers assessing preclinical anticancer activity 
should avoid experimental approaches that are poor 
predictors of activity in cancer patients (e.g., anticancer 
potency in malignant cells, or in vivo antitumor activity 
under deficient experimental conditions). Editors and 
reviewers of scientific journals, as well as grant decision 
makers, can play a crucial role in preventing researchers 
from following this type of approaches. They should 
consider requesting the in vitro and the in vivo tests 
when the goal of the research is to assess preclinical 
anticancer activity. Negative results obtained under 
suitable experimental conditions should find a place in 
research journals. This would encourage researchers to 
follow solid experimental designs, even though they are 
unlikely to lead to the desired result. In addition, negative 
results obtained under suitable experimental conditions 
can be more valuable than positive results obtained 
under poor experimental conditions. The publication of a 
paper demonstrating that a drug candidate has a limited 
therapeutic potential may prevent hundreds or even 
thousands of research works from being conducted; this 
would lead to an important saving of research resources 
that could be used for better purposes. The publication 
of a positive result obtained under poor experimental 
conditions may lead to costly and unnecessary preclinical 
and clinical research. 
Finally, it is important to note that the experimental 
conditions of these tests are set up to detect drug candidates 
that at least match the anticancer activity of the existing 
treatments. This is essential because only these drugs will 
have a chance of being ultimately used in cancer patients. 
It is easy to predict that most drug candidates will not pass 
the tests. An important consequence is that the number of 
perfect research papers showing a promising compound 
that kills cancer cells in vitro and in vivo by targeting a 
key cancer pathway would dramatically decrease. The 
aim of researchers and scientific journals involved in 
cancer drug discovery should not be to publish these 
perfect papers, but to carry out and disseminate research 
studies evaluating anticancer activity robustly. This would 
increase the possibilities of finding better anticancer drugs 
that we all might need.
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